

ASX ANNOUNCEMENT

NEW PATENTS FOR MIDKINE ANTIBODIES IN USA AND EUROPE

- **Patent covering Lynamid's antibody recognizing N-domain of midkine granted in USA**
- **European Patent Office issues intention to grant for midkine N-domain antibody patent**
- **Comprehensive protection over N-domain midkine antibodies to treat cancer, inflammatory and auto-immune diseases, and post-laparotomy adhesions**

SYDNEY, Wednesday, 7 NOVEMBER 2018: Cellmid Limited (ASX: CDY) is pleased to advise that the US Patent Office has granted Lynamid's patent application 14/004,548 entitled "Antibody recognizing N-domain of midkine". In further news, Cellmid has received 'Notification of Intention to Grant' from the European Patent Office for the corresponding patent in key European territories (EPO Application No. 12757658.5).

This patent family protects the composition of antibodies that recognize regions within the N-domain of midkine (MK) protein, as well as their use in several disease settings including cancer, inflammatory and autoimmune conditions.

The N-domain patent family complements the already granted Australian, USA and European patents entitled "Antibody recognizing C-domain of midkine " (CDY: ASX Announcement, 29 June 2015) covering the murine monoclonal antibody IP14. Together with the patent application "Improved midkine antibody" for CAB102, the humanised form of IP14 (PCT/AU2015/050629 - under examination), these related patents provide comprehensive protection for Cellmid's antibody assets.

The newly granted midkine antibody patents and allied patent families underpin the Company's dominant intellectual property position over the use of therapeutic midkine antibodies for the treatment of diseases arising from cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune diseases.

In addition to the broad clinical indications described above, the Company has recently filed two new provisional patent applications for Lynamid's N-domain antibodies; the first one covering the areas of accelerated bone healing following fractures, the second for the treatment of chronic inflammatory heart failure (myocarditis). These patent applications have been filed following research collaborations formed at the Midkine Symposia and highlight the potential for further deployment of Lynamid's intellectual property in clinically relevant scenarios.

Cellmid's total patent portfolio currently comprises 60 patents and applications in 13 patent families, including patents covering the use of MK and anti-MK agents for therapeutic purposes in a number of diseases such as cancer, inflammatory conditions and autoimmune diseases. In addition, the Company also holds patents covering the use of MK as a diagnostic marker in cancer and other disorders, which can be leveraged as a companion diagnostic, potentially accelerating clinical development.

END

| | |
|---|---|
| <p>Company Maria Halasz, CEO Cellmid T +612 9221 6830</p> | <p>Investor Relations & Media Rebecca Wilson WE Buchan T + 61 417 382 391 rwilson@we-buchan.com</p> |
|---|---|

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to this novel target is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.myevolus.com.au

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.